nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—Etoposide—uterine cancer	0.0996	0.181	CbGbCtD
Pomalidomide—CYP1A2—Progesterone—uterine cancer	0.084	0.152	CbGbCtD
Pomalidomide—ABCB1—Progesterone—uterine cancer	0.0734	0.133	CbGbCtD
Pomalidomide—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0664	0.12	CbGbCtD
Pomalidomide—ABCB1—Dactinomycin—uterine cancer	0.0582	0.106	CbGbCtD
Pomalidomide—CYP3A4—Progesterone—uterine cancer	0.044	0.0798	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—uterine cancer	0.0376	0.0681	CbGbCtD
Pomalidomide—ABCB1—Etoposide—uterine cancer	0.0329	0.0596	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—uterine cancer	0.0224	0.0406	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—uterine cancer	0.0197	0.0357	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—uterine cancer	0.0134	0.0243	CbGbCtD
Pomalidomide—Thalidomide—FGFR2—uterine cancer	0.0092	1	CrCbGaD
Pomalidomide—TNF—vagina—uterine cancer	0.00618	0.0814	CbGeAlD
Pomalidomide—CRBN—myometrium—uterine cancer	0.0056	0.0737	CbGeAlD
Pomalidomide—CRBN—uterine cervix—uterine cancer	0.00436	0.0574	CbGeAlD
Pomalidomide—CRBN—decidua—uterine cancer	0.00415	0.0547	CbGeAlD
Pomalidomide—CRBN—renal system—uterine cancer	0.00408	0.0537	CbGeAlD
Pomalidomide—TNF—lymph node—uterine cancer	0.004	0.0526	CbGeAlD
Pomalidomide—CRBN—endometrium—uterine cancer	0.00394	0.0519	CbGeAlD
Pomalidomide—CRBN—mammalian vulva—uterine cancer	0.00381	0.0502	CbGeAlD
Pomalidomide—CRBN—uterus—uterine cancer	0.00363	0.0478	CbGeAlD
Pomalidomide—CRBN—female reproductive system—uterine cancer	0.00327	0.043	CbGeAlD
Pomalidomide—PTGS2—artery—uterine cancer	0.00316	0.0416	CbGeAlD
Pomalidomide—CRBN—female gonad—uterine cancer	0.00297	0.0391	CbGeAlD
Pomalidomide—CRBN—vagina—uterine cancer	0.00295	0.0389	CbGeAlD
Pomalidomide—CRBN—lymph node—uterine cancer	0.00191	0.0252	CbGeAlD
Pomalidomide—PTGS2—myometrium—uterine cancer	0.00153	0.0201	CbGeAlD
Pomalidomide—CYP1A2—renal system—uterine cancer	0.00134	0.0176	CbGeAlD
Pomalidomide—PTGS2—epithelium—uterine cancer	0.0012	0.0158	CbGeAlD
Pomalidomide—PTGS2—uterine cervix—uterine cancer	0.00119	0.0156	CbGeAlD
Pomalidomide—PTGS2—smooth muscle tissue—uterine cancer	0.00115	0.0152	CbGeAlD
Pomalidomide—PTGS2—renal system—uterine cancer	0.00111	0.0146	CbGeAlD
Pomalidomide—PTGS2—endometrium—uterine cancer	0.00107	0.0141	CbGeAlD
Pomalidomide—PTGS2—uterus—uterine cancer	0.000989	0.013	CbGeAlD
Pomalidomide—CYP3A4—renal system—uterine cancer	0.00097	0.0128	CbGeAlD
Pomalidomide—ABCB1—myometrium—uterine cancer	0.000943	0.0124	CbGeAlD
Pomalidomide—PTGS2—female reproductive system—uterine cancer	0.000889	0.0117	CbGeAlD
Pomalidomide—PTGS2—female gonad—uterine cancer	0.000809	0.0107	CbGeAlD
Pomalidomide—PTGS2—vagina—uterine cancer	0.000804	0.0106	CbGeAlD
Pomalidomide—CYP3A4—female reproductive system—uterine cancer	0.000777	0.0102	CbGeAlD
Pomalidomide—ABCB1—epithelium—uterine cancer	0.000741	0.00975	CbGeAlD
Pomalidomide—ABCB1—uterine cervix—uterine cancer	0.000734	0.00967	CbGeAlD
Pomalidomide—ABCB1—decidua—uterine cancer	0.0007	0.00921	CbGeAlD
Pomalidomide—ABCB1—renal system—uterine cancer	0.000687	0.00904	CbGeAlD
Pomalidomide—ABCB1—endometrium—uterine cancer	0.000664	0.00874	CbGeAlD
Pomalidomide—ABCB1—mammalian vulva—uterine cancer	0.000642	0.00846	CbGeAlD
Pomalidomide—ABCB1—uterus—uterine cancer	0.000612	0.00806	CbGeAlD
Pomalidomide—Fatigue—Progesterone—uterine cancer	0.000591	0.00206	CcSEcCtD
Pomalidomide—Pain—Progesterone—uterine cancer	0.000586	0.00204	CcSEcCtD
Pomalidomide—Constipation—Progesterone—uterine cancer	0.000586	0.00204	CcSEcCtD
Pomalidomide—Pancytopenia—Etoposide—uterine cancer	0.000586	0.00204	CcSEcCtD
Pomalidomide—Neutropenia—Etoposide—uterine cancer	0.000577	0.00201	CcSEcCtD
Pomalidomide—Bone pain—Epirubicin—uterine cancer	0.000575	0.002	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000566	0.00197	CcSEcCtD
Pomalidomide—Feeling abnormal—Progesterone—uterine cancer	0.000565	0.00197	CcSEcCtD
Pomalidomide—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000562	0.00196	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.000561	0.00195	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Epirubicin—uterine cancer	0.000558	0.00194	CcSEcCtD
Pomalidomide—Hypocalcaemia—Doxorubicin—uterine cancer	0.000557	0.00194	CcSEcCtD
Pomalidomide—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000554	0.00193	CcSEcCtD
Pomalidomide—Pneumonia—Etoposide—uterine cancer	0.000553	0.00193	CcSEcCtD
Pomalidomide—Pulmonary embolism—Epirubicin—uterine cancer	0.000551	0.00192	CcSEcCtD
Pomalidomide—ABCB1—female reproductive system—uterine cancer	0.00055	0.00724	CbGeAlD
Pomalidomide—Infestation NOS—Etoposide—uterine cancer	0.00055	0.00192	CcSEcCtD
Pomalidomide—Infestation—Etoposide—uterine cancer	0.00055	0.00192	CcSEcCtD
Pomalidomide—Anaemia—Dactinomycin—uterine cancer	0.000549	0.00191	CcSEcCtD
Pomalidomide—Body temperature increased—Progesterone—uterine cancer	0.000542	0.00189	CcSEcCtD
Pomalidomide—Hyperkalaemia—Epirubicin—uterine cancer	0.000541	0.00189	CcSEcCtD
Pomalidomide—Renal failure—Etoposide—uterine cancer	0.00054	0.00188	CcSEcCtD
Pomalidomide—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00054	0.00188	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Etoposide—uterine cancer	0.000539	0.00188	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000536	0.00187	CcSEcCtD
Pomalidomide—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000536	0.00187	CcSEcCtD
Pomalidomide—Bone pain—Doxorubicin—uterine cancer	0.000532	0.00185	CcSEcCtD
Pomalidomide—Leukopenia—Dactinomycin—uterine cancer	0.000531	0.00185	CcSEcCtD
Pomalidomide—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000531	0.00185	CcSEcCtD
Pomalidomide—PTGS2—lymph node—uterine cancer	0.00052	0.00685	CbGeAlD
Pomalidomide—Hepatobiliary disease—Etoposide—uterine cancer	0.00052	0.00181	CcSEcCtD
Pomalidomide—Neuropathy—Epirubicin—uterine cancer	0.000517	0.0018	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Doxorubicin—uterine cancer	0.000516	0.0018	CcSEcCtD
Pomalidomide—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000512	0.00178	CcSEcCtD
Pomalidomide—Pulmonary embolism—Doxorubicin—uterine cancer	0.00051	0.00178	CcSEcCtD
Pomalidomide—Hypersensitivity—Progesterone—uterine cancer	0.000505	0.00176	CcSEcCtD
Pomalidomide—Hyperkalaemia—Doxorubicin—uterine cancer	0.000501	0.00175	CcSEcCtD
Pomalidomide—ABCB1—female gonad—uterine cancer	0.000501	0.00659	CbGeAlD
Pomalidomide—ABCB1—vagina—uterine cancer	0.000498	0.00655	CbGeAlD
Pomalidomide—Asthenia—Progesterone—uterine cancer	0.000492	0.00171	CcSEcCtD
Pomalidomide—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000491	0.00171	CcSEcCtD
Pomalidomide—Urinary tract disorder—Etoposide—uterine cancer	0.000487	0.0017	CcSEcCtD
Pomalidomide—Pruritus—Progesterone—uterine cancer	0.000485	0.00169	CcSEcCtD
Pomalidomide—Urethral disorder—Etoposide—uterine cancer	0.000484	0.00169	CcSEcCtD
Pomalidomide—Infection—Dactinomycin—uterine cancer	0.000481	0.00168	CcSEcCtD
Pomalidomide—Neuropathy—Doxorubicin—uterine cancer	0.000479	0.00167	CcSEcCtD
Pomalidomide—Sepsis—Epirubicin—uterine cancer	0.000478	0.00167	CcSEcCtD
Pomalidomide—Thrombocytopenia—Dactinomycin—uterine cancer	0.000474	0.00165	CcSEcCtD
Pomalidomide—Diarrhoea—Progesterone—uterine cancer	0.000469	0.00163	CcSEcCtD
Pomalidomide—Cardiac disorder—Etoposide—uterine cancer	0.000458	0.0016	CcSEcCtD
Pomalidomide—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000458	0.0016	CcSEcCtD
Pomalidomide—Dizziness—Progesterone—uterine cancer	0.000453	0.00158	CcSEcCtD
Pomalidomide—Angiopathy—Etoposide—uterine cancer	0.000448	0.00156	CcSEcCtD
Pomalidomide—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000446	0.00155	CcSEcCtD
Pomalidomide—Mediastinal disorder—Etoposide—uterine cancer	0.000445	0.00155	CcSEcCtD
Pomalidomide—Chills—Etoposide—uterine cancer	0.000443	0.00154	CcSEcCtD
Pomalidomide—Sepsis—Doxorubicin—uterine cancer	0.000442	0.00154	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000441	0.00154	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Epirubicin—uterine cancer	0.000441	0.00154	CcSEcCtD
Pomalidomide—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000439	0.00153	CcSEcCtD
Pomalidomide—Vomiting—Progesterone—uterine cancer	0.000436	0.00152	CcSEcCtD
Pomalidomide—Rash—Progesterone—uterine cancer	0.000432	0.00151	CcSEcCtD
Pomalidomide—Dermatitis—Progesterone—uterine cancer	0.000432	0.00151	CcSEcCtD
Pomalidomide—Headache—Progesterone—uterine cancer	0.000429	0.0015	CcSEcCtD
Pomalidomide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000425	0.00148	CcSEcCtD
Pomalidomide—Decreased appetite—Dactinomycin—uterine cancer	0.000421	0.00147	CcSEcCtD
Pomalidomide—Fatigue—Dactinomycin—uterine cancer	0.000418	0.00146	CcSEcCtD
Pomalidomide—Back pain—Etoposide—uterine cancer	0.000416	0.00145	CcSEcCtD
Pomalidomide—Pain—Dactinomycin—uterine cancer	0.000414	0.00144	CcSEcCtD
Pomalidomide—Muscle spasms—Etoposide—uterine cancer	0.000413	0.00144	CcSEcCtD
Pomalidomide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000411	0.00143	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000408	0.00142	CcSEcCtD
Pomalidomide—Nausea—Progesterone—uterine cancer	0.000407	0.00142	CcSEcCtD
Pomalidomide—Hyponatraemia—Epirubicin—uterine cancer	0.000402	0.0014	CcSEcCtD
Pomalidomide—Pain in extremity—Epirubicin—uterine cancer	0.0004	0.00139	CcSEcCtD
Pomalidomide—Feeling abnormal—Dactinomycin—uterine cancer	0.000399	0.00139	CcSEcCtD
Pomalidomide—Anaemia—Etoposide—uterine cancer	0.000397	0.00138	CcSEcCtD
Pomalidomide—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000395	0.00138	CcSEcCtD
Pomalidomide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000392	0.00137	CcSEcCtD
Pomalidomide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000391	0.00136	CcSEcCtD
Pomalidomide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000389	0.00136	CcSEcCtD
Pomalidomide—Vertigo—Etoposide—uterine cancer	0.000386	0.00135	CcSEcCtD
Pomalidomide—Leukopenia—Etoposide—uterine cancer	0.000385	0.00134	CcSEcCtD
Pomalidomide—Body temperature increased—Dactinomycin—uterine cancer	0.000383	0.00134	CcSEcCtD
Pomalidomide—Cough—Etoposide—uterine cancer	0.000375	0.00131	CcSEcCtD
Pomalidomide—Blood creatinine increased—Epirubicin—uterine cancer	0.000375	0.00131	CcSEcCtD
Pomalidomide—Dehydration—Epirubicin—uterine cancer	0.000372	0.0013	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—uterine cancer	0.000372	0.0013	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—uterine cancer	0.00037	0.00129	CcSEcCtD
Pomalidomide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000369	0.00129	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—uterine cancer	0.000367	0.00128	CcSEcCtD
Pomalidomide—Hypokalaemia—Epirubicin—uterine cancer	0.000364	0.00127	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000363	0.00127	CcSEcCtD
Pomalidomide—Breast disorder—Epirubicin—uterine cancer	0.000361	0.00126	CcSEcCtD
Pomalidomide—Nasopharyngitis—Epirubicin—uterine cancer	0.000358	0.00125	CcSEcCtD
Pomalidomide—Hypersensitivity—Dactinomycin—uterine cancer	0.000357	0.00124	CcSEcCtD
Pomalidomide—Confusional state—Etoposide—uterine cancer	0.000354	0.00123	CcSEcCtD
Pomalidomide—Muscular weakness—Epirubicin—uterine cancer	0.000353	0.00123	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000353	0.00123	CcSEcCtD
Pomalidomide—Infection—Etoposide—uterine cancer	0.000348	0.00121	CcSEcCtD
Pomalidomide—Asthenia—Dactinomycin—uterine cancer	0.000348	0.00121	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—uterine cancer	0.000347	0.00121	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—uterine cancer	0.000344	0.0012	CcSEcCtD
Pomalidomide—Thrombocytopenia—Etoposide—uterine cancer	0.000343	0.0012	CcSEcCtD
Pomalidomide—Skin disorder—Etoposide—uterine cancer	0.000341	0.00119	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—uterine cancer	0.000339	0.00118	CcSEcCtD
Pomalidomide—Hyperhidrosis—Etoposide—uterine cancer	0.000339	0.00118	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—uterine cancer	0.000337	0.00117	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—uterine cancer	0.000334	0.00117	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—uterine cancer	0.000332	0.00116	CcSEcCtD
Pomalidomide—Diarrhoea—Dactinomycin—uterine cancer	0.000332	0.00116	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—uterine cancer	0.000331	0.00115	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—uterine cancer	0.000328	0.00114	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000326	0.00114	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—uterine cancer	0.000326	0.00114	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—uterine cancer	0.000323	0.00113	CcSEcCtD
Pomalidomide—ABCB1—lymph node—uterine cancer	0.000322	0.00424	CbGeAlD
Pomalidomide—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000321	0.00112	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—uterine cancer	0.000315	0.0011	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—uterine cancer	0.000313	0.00109	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—uterine cancer	0.000313	0.00109	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—uterine cancer	0.000312	0.00109	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—uterine cancer	0.00031	0.00108	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—uterine cancer	0.000308	0.00107	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—uterine cancer	0.000308	0.00107	CcSEcCtD
Pomalidomide—Vomiting—Dactinomycin—uterine cancer	0.000308	0.00107	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—uterine cancer	0.000308	0.00107	CcSEcCtD
Pomalidomide—Rash—Dactinomycin—uterine cancer	0.000305	0.00106	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—uterine cancer	0.000305	0.00106	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—uterine cancer	0.000304	0.00106	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—uterine cancer	0.000303	0.00106	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—uterine cancer	0.000303	0.00106	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—uterine cancer	0.000302	0.00105	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—uterine cancer	0.000302	0.00105	CcSEcCtD
Pomalidomide—Pain—Etoposide—uterine cancer	0.0003	0.00105	CcSEcCtD
Pomalidomide—Constipation—Etoposide—uterine cancer	0.0003	0.00105	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—uterine cancer	0.0003	0.00104	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—uterine cancer	0.000299	0.00104	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000297	0.00104	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—uterine cancer	0.000291	0.00102	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—uterine cancer	0.000291	0.00101	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—uterine cancer	0.000291	0.00101	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—uterine cancer	0.000289	0.00101	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—uterine cancer	0.000289	0.00101	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—uterine cancer	0.000289	0.00101	CcSEcCtD
Pomalidomide—Nausea—Dactinomycin—uterine cancer	0.000288	0.001	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—uterine cancer	0.000287	0.001	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—uterine cancer	0.000285	0.000994	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—uterine cancer	0.000285	0.000994	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—uterine cancer	0.00028	0.000977	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—uterine cancer	0.00028	0.000974	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—uterine cancer	0.000277	0.000966	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—uterine cancer	0.000277	0.000966	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—uterine cancer	0.000273	0.000952	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—uterine cancer	0.000273	0.00095	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—uterine cancer	0.000272	0.000948	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—uterine cancer	0.000271	0.000945	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—uterine cancer	0.00027	0.00094	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—uterine cancer	0.000269	0.000938	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—uterine cancer	0.000258	0.000901	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—uterine cancer	0.000257	0.000895	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—uterine cancer	0.000253	0.000881	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—uterine cancer	0.000252	0.000879	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—uterine cancer	0.000252	0.000877	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—uterine cancer	0.000252	0.000877	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—uterine cancer	0.000251	0.000875	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—uterine cancer	0.000251	0.000875	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—uterine cancer	0.000249	0.000869	CcSEcCtD
Pomalidomide—Chills—Epirubicin—uterine cancer	0.000248	0.000865	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—uterine cancer	0.000248	0.000865	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—uterine cancer	0.000242	0.000845	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—uterine cancer	0.000241	0.00084	CcSEcCtD
Pomalidomide—Diarrhoea—Etoposide—uterine cancer	0.00024	0.000836	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—uterine cancer	0.000238	0.000828	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—uterine cancer	0.000233	0.000812	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—uterine cancer	0.000232	0.00081	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—uterine cancer	0.000232	0.000808	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—uterine cancer	0.000232	0.000807	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—uterine cancer	0.000231	0.000804	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—uterine cancer	0.00023	0.000801	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—uterine cancer	0.000224	0.000782	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—uterine cancer	0.000223	0.000777	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—uterine cancer	0.000223	0.000777	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—uterine cancer	0.000223	0.000776	CcSEcCtD
Pomalidomide—Rash—Etoposide—uterine cancer	0.000221	0.000771	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—uterine cancer	0.000221	0.00077	CcSEcCtD
Pomalidomide—Headache—Etoposide—uterine cancer	0.00022	0.000766	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—uterine cancer	0.000216	0.000754	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—uterine cancer	0.000216	0.000751	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—uterine cancer	0.000216	0.000751	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—uterine cancer	0.000214	0.000747	CcSEcCtD
Pomalidomide—Cough—Epirubicin—uterine cancer	0.00021	0.000733	CcSEcCtD
Pomalidomide—Nausea—Etoposide—uterine cancer	0.000208	0.000726	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—uterine cancer	0.000206	0.000718	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—uterine cancer	0.000205	0.000715	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—uterine cancer	0.000204	0.000712	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000204	0.00071	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—uterine cancer	0.0002	0.000698	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—uterine cancer	0.000199	0.000695	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—uterine cancer	0.000198	0.000691	CcSEcCtD
Pomalidomide—Infection—Epirubicin—uterine cancer	0.000195	0.000681	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—uterine cancer	0.000194	0.000678	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—uterine cancer	0.000193	0.000672	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—uterine cancer	0.000192	0.000671	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—uterine cancer	0.000191	0.000666	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—uterine cancer	0.00019	0.000662	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—uterine cancer	0.00019	0.000661	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—uterine cancer	0.000189	0.000659	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000188	0.000657	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—uterine cancer	0.000183	0.000639	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—uterine cancer	0.000181	0.00063	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—KRAS—uterine cancer	0.00018	0.00235	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—HRAS—uterine cancer	0.000179	0.00235	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000179	0.000624	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—uterine cancer	0.000178	0.000622	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—uterine cancer	0.000178	0.000621	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—uterine cancer	0.000178	0.00062	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—uterine cancer	0.000177	0.000616	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—uterine cancer	0.000176	0.000613	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000176	0.0023	CbGpPWpGaD
Pomalidomide—Dyspnoea—Epirubicin—uterine cancer	0.000175	0.000611	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000174	0.00229	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000174	0.00228	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—AKT1—uterine cancer	0.000174	0.00228	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000172	0.00226	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000171	0.00224	CbGpPWpGaD
Pomalidomide—Decreased appetite—Epirubicin—uterine cancer	0.000171	0.000596	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00017	0.000592	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—uterine cancer	0.000169	0.000591	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.000169	0.00222	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—uterine cancer	0.000168	0.0022	CbGpPWpGaD
Pomalidomide—Pain—Epirubicin—uterine cancer	0.000168	0.000586	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—uterine cancer	0.000168	0.000586	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000166	0.000578	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—uterine cancer	0.000164	0.000573	CcSEcCtD
Pomalidomide—TNF—Apoptosis—CDH1—uterine cancer	0.000164	0.00215	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	0.000164	0.00215	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CXCL8—uterine cancer	0.000163	0.00214	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000163	0.00214	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000163	0.00213	CbGpPWpGaD
Pomalidomide—Dyspnoea—Doxorubicin—uterine cancer	0.000162	0.000565	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—uterine cancer	0.000162	0.000565	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	0.000162	0.00212	CbGpPWpGaD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000161	0.00211	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—uterine cancer	0.000161	0.0021	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NRAS—uterine cancer	0.00016	0.00209	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.00016	0.00209	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—uterine cancer	0.00016	0.00209	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CDKN1B—uterine cancer	0.00016	0.00209	CbGpPWpGaD
Pomalidomide—Decreased appetite—Doxorubicin—uterine cancer	0.000158	0.000551	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.000157	0.00206	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000157	0.000547	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—uterine cancer	0.000157	0.000547	CcSEcCtD
Pomalidomide—TNF—Cardiac Hypertrophic Response—AKT1—uterine cancer	0.000156	0.00204	CbGpPWpGaD
Pomalidomide—Pain—Doxorubicin—uterine cancer	0.000156	0.000542	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—uterine cancer	0.000156	0.000542	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—uterine cancer	0.000155	0.000542	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—uterine cancer	0.000153	0.002	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—uterine cancer	0.000151	0.00198	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Doxorubicin—uterine cancer	0.00015	0.000522	CcSEcCtD
Pomalidomide—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	0.00015	0.00196	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000148	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000148	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000146	0.00192	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Epirubicin—uterine cancer	0.000145	0.000505	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—uterine cancer	0.000144	0.000501	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—uterine cancer	0.000143	0.00188	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000141	0.00185	CbGpPWpGaD
Pomalidomide—Asthenia—Epirubicin—uterine cancer	0.000141	0.000492	CcSEcCtD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00014	0.00184	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00014	0.00184	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CTNNB1—uterine cancer	0.000139	0.00183	CbGpPWpGaD
Pomalidomide—Pruritus—Epirubicin—uterine cancer	0.000139	0.000485	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—TP53—uterine cancer	0.000138	0.00181	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—KRAS—uterine cancer	0.000138	0.0018	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—PIK3CA—uterine cancer	0.000136	0.00178	CbGpPWpGaD
Pomalidomide—Diarrhoea—Epirubicin—uterine cancer	0.000134	0.000469	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—uterine cancer	0.000134	0.000467	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000132	0.00174	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000132	0.00173	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—uterine cancer	0.000132	0.00172	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	0.000131	0.00172	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.000131	0.00171	CbGpPWpGaD
Pomalidomide—Asthenia—Doxorubicin—uterine cancer	0.00013	0.000455	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—uterine cancer	0.00013	0.000453	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	0.000129	0.0017	CbGpPWpGaD
Pomalidomide—Pruritus—Doxorubicin—uterine cancer	0.000129	0.000449	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	0.000128	0.00167	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000126	0.00165	CbGpPWpGaD
Pomalidomide—Vomiting—Epirubicin—uterine cancer	0.000125	0.000436	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000124	0.00163	CbGpPWpGaD
Pomalidomide—Diarrhoea—Doxorubicin—uterine cancer	0.000124	0.000434	CcSEcCtD
Pomalidomide—Rash—Epirubicin—uterine cancer	0.000124	0.000432	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—uterine cancer	0.000124	0.000432	CcSEcCtD
Pomalidomide—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	0.000124	0.00162	CbGpPWpGaD
Pomalidomide—Headache—Epirubicin—uterine cancer	0.000123	0.000429	CcSEcCtD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000122	0.0016	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CTNNB1—uterine cancer	0.000121	0.00159	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.000121	0.00158	CbGpPWpGaD
Pomalidomide—Dizziness—Doxorubicin—uterine cancer	0.00012	0.000419	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000119	0.00155	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000119	0.00155	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000117	0.00153	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—HRAS—uterine cancer	0.000117	0.00153	CbGpPWpGaD
Pomalidomide—Nausea—Epirubicin—uterine cancer	0.000117	0.000407	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—PIK3CA—uterine cancer	0.000116	0.00153	CbGpPWpGaD
Pomalidomide—Vomiting—Doxorubicin—uterine cancer	0.000116	0.000403	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.000115	0.00151	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000115	0.00151	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000115	0.00151	CbGpPWpGaD
Pomalidomide—Rash—Doxorubicin—uterine cancer	0.000115	0.0004	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—uterine cancer	0.000115	0.000399	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—uterine cancer	0.000114	0.000397	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	0.000114	0.00149	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—EP300—uterine cancer	0.000112	0.00147	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—uterine cancer	0.000111	0.00146	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—uterine cancer	0.000111	0.00146	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.00011	0.00144	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000109	0.00142	CbGpPWpGaD
Pomalidomide—Nausea—Doxorubicin—uterine cancer	0.000108	0.000377	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	0.000106	0.00139	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.000106	0.00139	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000105	0.00137	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000104	0.00136	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000104	0.00136	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—AKT1—uterine cancer	0.000103	0.00135	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000103	0.00135	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000103	0.00134	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	0.000101	0.00133	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	0.000101	0.00132	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—uterine cancer	0.0001	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	9.99e-05	0.00131	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NRAS—uterine cancer	9.88e-05	0.00129	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	9.87e-05	0.00129	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CXCL8—uterine cancer	9.87e-05	0.00129	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	9.86e-05	0.00129	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	9.86e-05	0.00129	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	9.77e-05	0.00128	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	9.74e-05	0.00128	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	9.54e-05	0.00125	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	9.53e-05	0.00125	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—uterine cancer	9.51e-05	0.00125	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	9.45e-05	0.00124	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	9.41e-05	0.00123	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	9.39e-05	0.00123	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	9.26e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	9.15e-05	0.0012	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—SMAD3—uterine cancer	9.15e-05	0.0012	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	9.1e-05	0.00119	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—PIK3CA—uterine cancer	9.09e-05	0.00119	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	9.02e-05	0.00118	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	8.97e-05	0.00118	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	8.89e-05	0.00116	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SRD5A2—uterine cancer	8.64e-05	0.00113	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NDUFB11—uterine cancer	8.64e-05	0.00113	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—KRAS—uterine cancer	8.5e-05	0.00111	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	8.39e-05	0.0011	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	8.39e-05	0.0011	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—uterine cancer	8.06e-05	0.00106	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKR1B10—uterine cancer	8.02e-05	0.00105	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—uterine cancer	8.02e-05	0.00105	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	7.93e-05	0.00104	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	7.93e-05	0.00104	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	7.92e-05	0.00104	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	7.78e-05	0.00102	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	7.67e-05	0.00101	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—uterine cancer	7.56e-05	0.00099	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MET—uterine cancer	7.49e-05	0.000982	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—uterine cancer	7.42e-05	0.000973	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	7.25e-05	0.000949	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	7.13e-05	0.000934	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	7.05e-05	0.000923	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	7.02e-05	0.00092	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	7e-05	0.000917	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	6.92e-05	0.000907	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	6.82e-05	0.000893	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—uterine cancer	6.8e-05	0.000891	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	6.71e-05	0.000879	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RNF43—uterine cancer	6.65e-05	0.000871	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—uterine cancer	6.38e-05	0.000836	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	6.34e-05	0.000831	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—STAR—uterine cancer	6.24e-05	0.000818	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKR1B1—uterine cancer	6.24e-05	0.000818	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—uterine cancer	6.2e-05	0.000812	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	6.18e-05	0.000809	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	6.17e-05	0.000809	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SRD5A2—uterine cancer	6.12e-05	0.000802	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NDUFB11—uterine cancer	6.12e-05	0.000802	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	5.91e-05	0.000774	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.89e-05	0.000772	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5.82e-05	0.000763	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.76e-05	0.000754	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	5.58e-05	0.000731	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ERBB2—uterine cancer	5.48e-05	0.000718	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKR1C1—uterine cancer	5.47e-05	0.000717	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	5.14e-05	0.000673	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—POLD1—uterine cancer	4.9e-05	0.000642	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NDUFB11—uterine cancer	4.89e-05	0.00064	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SRD5A2—uterine cancer	4.89e-05	0.00064	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—uterine cancer	4.79e-05	0.000628	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	4.76e-05	0.000623	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.75e-05	0.000622	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.74e-05	0.000622	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—DCN—uterine cancer	4.74e-05	0.00062	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKR1C1—uterine cancer	4.58e-05	0.0006	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	4.49e-05	0.000589	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.48e-05	0.000587	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EP300—uterine cancer	4.45e-05	0.000584	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—STAR—uterine cancer	4.43e-05	0.00058	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKR1B1—uterine cancer	4.43e-05	0.00058	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	4.38e-05	0.000574	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	4.36e-05	0.000571	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—uterine cancer	4.22e-05	0.000553	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	4.22e-05	0.000552	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKR1C3—uterine cancer	4.21e-05	0.000552	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	4.18e-05	0.000547	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NRAS—uterine cancer	4.17e-05	0.000546	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HMGA1—uterine cancer	4.11e-05	0.000538	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RRM2—uterine cancer	4.08e-05	0.000535	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—DCN—uterine cancer	3.97e-05	0.00052	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	3.96e-05	0.000518	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.77e-05	0.000494	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.77e-05	0.000494	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FBXW7—uterine cancer	3.75e-05	0.000492	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP11A1—uterine cancer	3.74e-05	0.000489	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—uterine cancer	3.59e-05	0.00047	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.56e-05	0.000466	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—STAR—uterine cancer	3.53e-05	0.000463	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKR1B1—uterine cancer	3.53e-05	0.000463	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKR1C3—uterine cancer	3.53e-05	0.000462	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.49e-05	0.000458	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—POLD1—uterine cancer	3.47e-05	0.000455	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	3.36e-05	0.000441	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKR1C1—uterine cancer	3.25e-05	0.000426	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.09e-05	0.000405	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—uterine cancer	3.05e-05	0.000399	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.99e-05	0.000392	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN2B—uterine cancer	2.94e-05	0.000385	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RRM2—uterine cancer	2.9e-05	0.000379	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—DCN—uterine cancer	2.81e-05	0.000368	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—POLD1—uterine cancer	2.77e-05	0.000363	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—STK11—uterine cancer	2.75e-05	0.00036	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP19A1—uterine cancer	2.75e-05	0.00036	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—STAR—uterine cancer	2.73e-05	0.000357	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.73e-05	0.000357	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—uterine cancer	2.69e-05	0.000353	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SMAD3—uterine cancer	2.69e-05	0.000352	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP11A1—uterine cancer	2.65e-05	0.000347	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKR1C1—uterine cancer	2.59e-05	0.00034	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.58e-05	0.000338	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR2—uterine cancer	2.56e-05	0.000336	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.52e-05	0.000331	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKR1C3—uterine cancer	2.5e-05	0.000328	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—uterine cancer	2.47e-05	0.000323	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.46e-05	0.000322	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RRM2—uterine cancer	2.31e-05	0.000303	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—DCN—uterine cancer	2.24e-05	0.000294	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—POLD1—uterine cancer	2.14e-05	0.00028	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP11A1—uterine cancer	2.11e-05	0.000277	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—uterine cancer	2.07e-05	0.000271	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKR1C1—uterine cancer	2e-05	0.000262	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKR1C3—uterine cancer	2e-05	0.000262	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—STK11—uterine cancer	1.95e-05	0.000255	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP19A1—uterine cancer	1.95e-05	0.000255	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.82e-05	0.000238	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RRM2—uterine cancer	1.78e-05	0.000234	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—DCN—uterine cancer	1.73e-05	0.000227	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.63e-05	0.000214	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—uterine cancer	1.61e-05	0.000211	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—STK11—uterine cancer	1.56e-05	0.000204	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP19A1—uterine cancer	1.56e-05	0.000204	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.54e-05	0.000202	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—uterine cancer	1.49e-05	0.000195	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—uterine cancer	1.46e-05	0.000192	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.46e-05	0.000191	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—uterine cancer	1.41e-05	0.000184	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.39e-05	0.000182	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—uterine cancer	1.37e-05	0.00018	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—uterine cancer	1.31e-05	0.000171	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—uterine cancer	1.22e-05	0.00016	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—STK11—uterine cancer	1.2e-05	0.000157	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.2e-05	0.000157	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—uterine cancer	1.17e-05	0.000153	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—uterine cancer	1.15e-05	0.000151	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—uterine cancer	1.1e-05	0.000144	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—uterine cancer	1.05e-05	0.000138	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.03e-05	0.000135	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—uterine cancer	9.68e-06	0.000127	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—uterine cancer	9.02e-06	0.000118	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—uterine cancer	8.96e-06	0.000117	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—uterine cancer	8.15e-06	0.000107	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—uterine cancer	8.11e-06	0.000106	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—uterine cancer	7.91e-06	0.000104	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—uterine cancer	7.77e-06	0.000102	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—uterine cancer	6.62e-06	8.68e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—uterine cancer	6.5e-06	8.52e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—uterine cancer	6.2e-06	8.12e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—uterine cancer	5.75e-06	7.53e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—uterine cancer	5.02e-06	6.57e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—uterine cancer	4.79e-06	6.27e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—uterine cancer	4.69e-06	6.15e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—uterine cancer	4.59e-06	6.01e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—uterine cancer	3.75e-06	4.91e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—uterine cancer	3.54e-06	4.64e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—uterine cancer	2.89e-06	3.79e-05	CbGpPWpGaD
